Patients with Crohn’s disease have traditionally been treated with anti-tumor necrosis factor therapy, such as infliximab. Surgery is usually reserved for people who do not respond to medication, experience adverse side effects, or develop complications of Crohn’s disease, such as fistulas or blockages. But a new trial showed that patients with limited, non-stricturing ileocecal Crohn’s disease who underwent ileocecal resection as a primary treatment had improvements in quality of life similar to those who took infliximab.
